Nintedanib is a medication used in this trial to help manage interstitial lung disease associated with systemic sclerosis. It works by slowing down the scarring process in the lungs, which can help improve breathing and lung function over time.

Rituximab is another medication being tested in the trial. It is an antibody therapy that targets specific cells in the immune system. By doing so, it may help reduce inflammation and slow down the progression of lung disease in patients with systemic sclerosis.

Abatacept is included in the trial as well. This medication works by interfering with the activity of certain immune cells that contribute to inflammation and tissue damage. It aims to help control the symptoms of interstitial lung disease in systemic sclerosis patients.

Tofacitinib is also part of the study. It is a medication that inhibits certain enzymes involved in the inflammatory process. By reducing inflammation, it may help improve lung function and overall health in patients with systemic sclerosis-related lung disease.

Interstitial Lung Disease Secondary to Systemic Sclerosis (SSc-ILD) – This disease is a type of lung condition that occurs as a complication of systemic sclerosis, a connective tissue disorder. It involves the scarring and thickening of lung tissues, which can lead to breathing difficulties. Over time, the lung’s ability to transfer oxygen into the bloodstream may decrease, causing shortness of breath and reduced exercise capacity. The progression of the disease can vary, with some individuals experiencing a slow decline in lung function, while others may have a more rapid progression. Symptoms often include a persistent dry cough and fatigue. The condition is considered rare and can significantly impact quality of life.